{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:29:10Z","timestamp":1791602950411,"version":"4.3.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000780","name":"EU","doi-asserted-by":"publisher","award":["965286"],"award-info":[{"award-number":["965286"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL131517"],"award-info":[{"award-number":["R01-HL131517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL136389"],"award-info":[{"award-number":["R01-HL136389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL089598"],"award-info":[{"award-number":["R01-HL089598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL163277"],"award-info":[{"award-number":["R01HL163277"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL160992"],"award-info":[{"award-number":["R01HL160992"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL165704"],"award-info":[{"award-number":["R01HL165704"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S2022\/BMD-7229"],"award-info":[{"award-number":["S2022\/BMD-7229"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic CVD and heart failure (HF). The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolaemia, type 2 diabetes, obesity, and HF; the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials. Finally, we end with a summary of the most important phase 2 and 3 clinical trials assessing the efficacy and safety of cardiovascular drugs under development for the prevention and treatment of CVDs.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvae013","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T08:33:31Z","timestamp":1708331611000},"page":"219-244","source":"Crossref","is-referenced-by-count":23,"title":["New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-7758","authenticated-orcid":false,"given":"Juan","family":"Tamargo","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto De Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , 28040 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Institute of Clinical Science, Oslo University , 0318 Oslo , Norway"},{"name":"Institute of Clinical Sciences, Karolinska Institute, Danderyd Hospital , 171 77 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S . Orsola, 40138 Bologna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ceconi","sequence":"additional","affiliation":[{"name":"Motusmed Clinic , 25122 Brescia , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-1361","authenticated-orcid":false,"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[{"name":"Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence , 50139 Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe A","family":"Dan","sequence":"additional","affiliation":[{"name":"Carol Davila. University of Medicine, Colentina University Hospital , 0221 Bucharest , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University , Budapest, H-1089 , Hungary"},{"name":"Pharmahungary Group , Budapest, H-1031 , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , 8200 Aarhus N , Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , 8200 Aarhus N , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence , 50139 Florence , Italy"},{"name":"Section of Pharmacology, Department of Safety and Bioethics, Catholic University School of Medicine , 00168 Roma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Magavern","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Centre of Clinical Pharmacology and Precision Medicine, Queen Mary University of London, Charterhouse Square , London EC1M 6BQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-0099","authenticated-orcid":false,"given":"Patrick","family":"Sulzgruber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical University of Vienna , 1090 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[{"name":"Preventive Cario-Rheuma clinic, Division of Research and Innovation, REMEDY centre, Diakonhjemmet Hospital , 0370 Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sossalla","sequence":"additional","affiliation":[{"name":"Cardiology and Angiology, Justus-Liebig-University , D-35392 Giessen , Germany"},{"name":"Department of Cardiology , Kerckhoff-Clinic\/DZHK, D-61234 Bad Nauheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-0935","authenticated-orcid":false,"given":"Alexander","family":"Niessner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna , 1090 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Research Institute, St. George's, University of London, Cranmer Terrace , London SW17 0RE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen , DE-45122 Essen , Germany"},{"name":"Department of Medicine, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , H1Y 3N1 Montr\u00e9al , Canada"},{"name":"Department of Integrative Physiology, Baylor College of Medicine , 77030 Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2024052412205754200_bib1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/eurjpc\/zwad038","article-title":"Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease","volume":"30","author":"Van Trier","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2024052412205754200_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"2024052412205754200_bib3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"2024052412205754200_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2024052412205754200_bib5","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC national cardiac societies, ESC scientific document group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Euro Heart J"},{"key":"2024052412205754200_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024052412205754200_bib7","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib8","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"SOLOIST-WHF trial investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"SCORED investigators. Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: Week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024052412205754200_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024052412205754200_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024052412205754200_bib14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"CLEAR outcomes investigators. bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"J Am Med Assoc"},{"key":"2024052412205754200_bib16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.7326\/M22-2643","article-title":"Association between age and low-density lipoprotein cholesterol response to statins\u202f: A danish nationwide cohort study","volume":"176","author":"Corn","year":"2023","journal-title":"Ann Intern Med"},{"key":"2024052412205754200_bib17","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: A report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024052412205754200_bib18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/jama.2023.2487","article-title":"LODESTAR Investigators. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial","volume":"329","author":"Hong","year":"2023","journal-title":"J Am Med Assoc"},{"key":"2024052412205754200_bib19","doi-asserted-by":"crossref","first-page":"e075837","DOI":"10.1136\/bmj-2023-075837","article-title":"LODESTAR investigators. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee","year":"2023","journal-title":"Br Med J"},{"key":"2024052412205754200_bib20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14779072.2023.2288169","article-title":"PCSK9 inhibitors: current status and emerging frontiers in lipid control","volume":"23","author":"Agnello","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2024052412205754200_bib21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024052412205754200_bib22","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"SELECT trial investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"2024052412205754200_bib24","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"STEP-HFpEF Trial committees and investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ehjcvp\/pvad034","article-title":"New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022","volume":"9","author":"Tamargo","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacoth"},{"key":"2024052412205754200_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"2024052412205754200_bib27","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"2024052412205754200_bib28","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"N Engl J Med Evid"},{"key":"2024052412205754200_bib29","doi-asserted-by":"crossref","first-page":"115033","DOI":"10.1016\/j.jep.2022.115033","article-title":"Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"289","author":"Lv","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"2024052412205754200_bib30","doi-asserted-by":"crossref","first-page":"e35405","DOI":"10.1097\/MD.0000000000035405","article-title":"Tongxinluo capsule in combination with conventional therapies for stable angina pectoris: a meta-analysis and systematic review","volume":"102","author":"Feng","year":"2023","journal-title":"Medicine"},{"key":"2024052412205754200_bib31","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2023.19524","article-title":"CTS-AMI Investigators. Traditional chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: The CTS-AMI randomized clinical trial","volume":"330","author":"Yang","year":"2023","journal-title":"J Am Med Assoc"},{"key":"2024052412205754200_bib32","doi-asserted-by":"crossref","first-page":"814222","DOI":"10.3389\/fmed.2021.814222","article-title":"Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-\u03b2 superfamily signaling","volume":"8","author":"Andre","year":"2021","journal-title":"Front Med"},{"key":"2024052412205754200_bib33","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib34","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2024052412205754200_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"2024052412205754200_bib36","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"Mcdonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2024052412205754200_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2014a position statement from the heart failure association of the European society of cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J of Heart Fail"},{"key":"2024052412205754200_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14779072.2022.2022474","article-title":"An evaluation of torsemide in patients with heart failure and renal disease","volume":"20","author":"Peters","year":"2022","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2024052412205754200_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: The TRANSFORM-HF randomized clinical trial","volume":"329","author":"Mentz","year":"2023","journal-title":"J Am Med Assoc"},{"key":"2024052412205754200_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2024052412205754200_bib41","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"2024052412205754200_bib42","volume-title":"Abelacimab, a novel factor XI\/XIa inhibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the AZALEA-TIMI 71 randomized trial","author":"Ruff"},{"key":"2024052412205754200_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2023","journal-title":"N Eng J Med"},{"key":"2024052412205754200_bib44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/CIRCRESAHA.120.316710","article-title":"Atrial myocyte NLRP3\/CaMKII nexus forms a substrate for postoperative atrial fibrillation","volume":"127","author":"Heijman","year":"2020","journal-title":"Circ Res"},{"key":"2024052412205754200_bib45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41569-022-00759-w","article-title":"Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology","volume":"20","author":"Dobrev","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2024052412205754200_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bja.2018.09.002","article-title":"Preoperative systemic inflammation and perioperative myocardial injury: prospective observational multicentre cohort study of patients undergoing non-cardiac surgery","volume":"122","author":"Ackland","year":"2019","journal-title":"Br J Anaesth"},{"key":"2024052412205754200_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41569-019-0166-5","article-title":"Postoperative atrial fibrillation: mechanisms, manifestations and management","volume":"16","author":"Dobrev","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"2024052412205754200_bib48","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(23)01689-6","article-title":"Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial","volume":"402","author":"Conen","year":"2023","journal-title":"Lancet"},{"key":"2024052412205754200_bib49","doi-asserted-by":"crossref","first-page":"euad166","DOI":"10.1093\/europace\/euad166","article-title":"The influence of atrial high-rate episodes on stroke and cardiovascular death: an update","volume":"25","author":"Toennis","year":"2023","journal-title":"Europace"},{"key":"2024052412205754200_bib50","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib51","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2024052412205754200_bib52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jamaneurol.2022.5088","article-title":"Effects of a polypill, aspirin, and the combination of both on cognitive and functional outcomes: a randomized clinical trial","volume":"80","author":"Bosch","year":"2023","journal-title":"JAMA Neurol"},{"key":"2024052412205754200_bib53","doi-asserted-by":"crossref","first-page":"e1619","DOI":"10.1016\/S2214-109X(23)00347-9","article-title":"A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial","volume":"11","author":"Sarfo","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2024052412205754200_bib54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","article-title":"Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024052412205754200_bib55","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2215\/CJN.0000000000000251","article-title":"Fixed-dose combination therapy for the prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis","volume":"18","author":"Sepanlou","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024052412205754200_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ehjcvp\/pvac005","article-title":"Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European society of cardiology working group on cardiovascular pharmacotherapy","volume":"8","author":"Tamargo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024052412205754200_bib57","first-page":"1507","article-title":"Polypharmacy and optimization of guideline-directed medical therapy in heart failure: the GUIDE-IT trial","volume":"11","author":"Khan","year":"2023","journal-title":"JACC: Heart Failure"},{"key":"2024052412205754200_bib58","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1770724","article-title":"Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis","author":"Zheng","year":"2023","journal-title":"Thromb Haemost"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae013\/56812518\/pvae013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/3\/219\/57701406\/pvae013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/3\/219\/57701406\/pvae013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T10:48:53Z","timestamp":1716547733000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/3\/219\/7611692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,20]]},"published-print":{"date-parts":[[2024,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae013","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,2,20]]}}}